219 related articles for article (PubMed ID: 27455835)
1. Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study.
Kumarathurai P; Anholm C; Nielsen OW; Kristiansen OP; Mølvig J; Madsbad S; Haugaard SB; Sajadieh A
Cardiovasc Diabetol; 2016 Jul; 15(1):105. PubMed ID: 27455835
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide-1 protects against ischemic left ventricular dysfunction during hyperglycemia in patients with coronary artery disease and type 2 diabetes mellitus.
McCormick LM; Heck PM; Ring LS; Kydd AC; Clarke SJ; Hoole SP; Dutka DP
Cardiovasc Diabetol; 2015 Aug; 14():102. PubMed ID: 26253538
[TBL] [Abstract][Full Text] [Related]
3. Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study.
Kumarathurai P; Sajadieh A; Anholm C; Kristiansen OP; Haugaard SB; Nielsen OW
Cardiovasc Diabetol; 2021 Jan; 20(1):12. PubMed ID: 33413428
[TBL] [Abstract][Full Text] [Related]
4. Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes (the AddHope2 study): a randomised controlled study protocol.
Anholm C; Kumarathurai P; Klit MS; Kristiansen OP; Nielsen OW; Ladelund S; Madsbad S; Sajadieh A; Haugaard SB;
BMJ Open; 2014 Jul; 4(7):e005942. PubMed ID: 25031198
[TBL] [Abstract][Full Text] [Related]
5. Design and rationale for the randomised, double-blinded, placebo-controlled Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS) crossover study.
Myat A; Arri S; Bhatt DL; Gersh BJ; Redwood SR; Marber MS
Cardiovasc Diabetol; 2015 Feb; 14():27. PubMed ID: 25848859
[TBL] [Abstract][Full Text] [Related]
6. Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes.
Lambadiari V; Pavlidis G; Kousathana F; Varoudi M; Vlastos D; Maratou E; Georgiou D; Andreadou I; Parissis J; Triantafyllidi H; Lekakis J; Iliodromitis E; Dimitriadis G; Ikonomidis I
Cardiovasc Diabetol; 2018 Jan; 17(1):8. PubMed ID: 29310645
[TBL] [Abstract][Full Text] [Related]
7. Effect of Liraglutide on Arterial Inflammation Assessed as [
Ripa RS; Zobel EH; von Scholten BJ; Jensen JK; Binderup T; Diaz LJ; Curovic VR; Hansen TW; Rossing P; Kjaer A
Circ Cardiovasc Imaging; 2021 Jul; 14(7):e012174. PubMed ID: 34187185
[TBL] [Abstract][Full Text] [Related]
8. Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial.
Bizino MB; Jazet IM; Westenberg JJM; van Eyk HJ; Paiman EHM; Smit JWA; Lamb HJ
Cardiovasc Diabetol; 2019 Apr; 18(1):55. PubMed ID: 31039778
[TBL] [Abstract][Full Text] [Related]
9. Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease.
McCormick LM; Kydd AC; Read PA; Ring LS; Bond SJ; Hoole SP; Dutka DP
Circ Cardiovasc Imaging; 2014 Mar; 7(2):274-81. PubMed ID: 24503784
[TBL] [Abstract][Full Text] [Related]
10. Metabolic improvement with short-term, glucagon-like peptide-1 receptor agonist treatment does not improve cardiac diastolic dysfunction in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial.
Bojer AS; Sørensen MH; Bjerre J; Gaede P; Vejlstrup N; Madsen PL
Diabetes Obes Metab; 2021 Oct; 23(10):2374-2384. PubMed ID: 34189832
[TBL] [Abstract][Full Text] [Related]
11. Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease: a randomized, double-blind, placebo-controlled, crossover study.
Kumarathurai P; Anholm C; Fabricius-Bjerre A; Nielsen OW; Kristiansen O; Madsbad S; Haugaard SB; Sajadieh A
J Hypertens; 2017 May; 35(5):1070-1078. PubMed ID: 28129251
[TBL] [Abstract][Full Text] [Related]
12. Effect of Liraglutide on Cardiovascular Function and Myocardial Tissue Characteristics in Type 2 Diabetes Patients of South Asian Descent Living in the Netherlands: A Double-Blind, Randomized, Placebo-Controlled Trial.
Paiman EHM; van Eyk HJ; van Aalst MMA; Bizino MB; van der Geest RJ; Westenberg JJM; Geelhoed-Duijvestijn PH; Kharagjitsingh AV; Rensen PCN; Smit JWA; Jazet IM; Lamb HJ
J Magn Reson Imaging; 2020 Jun; 51(6):1679-1688. PubMed ID: 31799782
[TBL] [Abstract][Full Text] [Related]
13. Effect of exercise combined with glucagon-like peptide-1 receptor agonist treatment on cardiac function: A randomized double-blind placebo-controlled clinical trial.
Jørgensen PG; Jensen MT; Mensberg P; Storgaard H; Nyby S; Jensen JS; Knop FK; Vilsbøll T
Diabetes Obes Metab; 2017 Jul; 19(7):1040-1044. PubMed ID: 28188972
[TBL] [Abstract][Full Text] [Related]
14. Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease.
Read PA; Khan FZ; Dutka DP
Heart; 2012 Mar; 98(5):408-13. PubMed ID: 21561896
[TBL] [Abstract][Full Text] [Related]
15. Systematic Review of Glucagon-Like Peptide One Receptor Agonist Liraglutide of Subjects with Heart Failure with Reduced Left Ventricular Ejection Fraction.
Hamad F; Elnour AA; Elamin A; Mohamed S; Yousif I; Don J; Abdi S; Al Amoodi A; Fathelrahman AI; Gnana K; Alanzi F; Abubakar AB; Magboul SM; Ahmed SA; Sadeq A
Curr Diabetes Rev; 2021; 17(3):280-292. PubMed ID: 32867644
[TBL] [Abstract][Full Text] [Related]
16. Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.
Anholm C; Kumarathurai P; Pedersen LR; Samkani A; Walzem RL; Nielsen OW; Kristiansen OP; Fenger M; Madsbad S; Sajadieh A; Haugaard SB
Atherosclerosis; 2019 Sep; 288():60-66. PubMed ID: 31326727
[TBL] [Abstract][Full Text] [Related]
17. Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS): a double-blind randomised placebo-controlled crossover trial.
Myat A; Redwood SR; Arri S; Gersh BJ; Bhatt DL; Marber MS
Diabetol Metab Syndr; 2021 Feb; 13(1):17. PubMed ID: 33579317
[TBL] [Abstract][Full Text] [Related]
18. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial.
Farr OM; Sofopoulos M; Tsoukas MA; Dincer F; Thakkar B; Sahin-Efe A; Filippaios A; Bowers J; Srnka A; Gavrieli A; Ko BJ; Liakou C; Kanyuch N; Tseleni-Balafouta S; Mantzoros CS
Diabetologia; 2016 May; 59(5):954-65. PubMed ID: 26831302
[TBL] [Abstract][Full Text] [Related]
19. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
Ikonomidis I; Pavlidis G; Thymis J; Birba D; Kalogeris A; Kousathana F; Kountouri A; Balampanis K; Parissis J; Andreadou I; Katogiannis K; Dimitriadis G; Bamias A; Iliodromitis E; Lambadiari V
J Am Heart Assoc; 2020 May; 9(9):e015716. PubMed ID: 32326806
[TBL] [Abstract][Full Text] [Related]
20. Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study.
Nielsen R; Jorsal A; Iversen P; Tolbod LP; Bouchelouche K; Sørensen J; Harms HJ; Flyvbjerg A; Tarnow L; Kistorp C; Gustafsson I; Bøtker HE; Wiggers H
J Nucl Cardiol; 2019 Apr; 26(2):585-597. PubMed ID: 28770459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
